急性髓系白血病 中国就医指南

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid proliferation and accumulation of abnormal, immature myeloid progenitor cells—blasts—in the bone marrow and peripheral blood. These malignant blasts impair normal hematopoiesis, leading to cytopenias (anemia, neutropenia, thrombocytopenia) and systemic consequences including infection, bleeding, and organ infiltration. AML arises from acquired somatic mutations in hematopoietic stem or progenitor cells, commonly involving genes such as FLT3, NPM1, CEBPA, IDH1/2, DNMT3A, and TP53. Pathogenesis involves a stepwise accumulation of genetic and epigenetic alterations that confer survival advantage, blocked differentiation, and uncontrolled self-renewal. Clonal evolution and microenvironmental dysregulation further contribute to treatment resistance and relapse. Epidemiologically, AML accounts for approximately 80% of acute leukemias in adults and has an annual incidence of 3–5 cases per 100,000 people in Western populations; incidence rises sharply after age 60, with median diagnosis age at 68 years. In China, age-standardized incidence is slightly lower (2.1–2.7 per 100,000), but absolute case numbers are substantial due to population size and aging demographics. Risk factors include prior exposure to ionizing radiation or chemotherapy (especially alkylating agents and topoisomerase II inhibitors), benzene and other industrial solvents, smoking, myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms, and inherited predisposition syndromes (e.g., Fanconi anemia, Down syndrome, RUNX1 familial platelet disorder). While most cases are sporadic, germline variants in genes like DDX41 and CEBPA are increasingly recognized. Quality of life (QoL) in AML is profoundly impacted—not only during intensive induction chemotherapy (with risks of sepsis, mucositis, prolonged hospitalization, and ICU admission) but also across survivorship phases. Fatigue, cognitive impairment ('chemo brain'), anxiety, depression, financial toxicity, and social isolation are prevalent. Long-term survivors may face infertility, secondary malignancies, cardiovascular complications, and persistent neurocognitive deficits. Supportive care—including psychosocial oncology, nutritional support, rehabilitation, and palliative integration—is integral to modern AML management. Early referral to specialized hematology centers significantly improves outcomes through risk-adapted therapy, access to clinical trials, and multidisciplinary expertise.

# 急性髓系白血病（AML）治疗方案与费用明细（血液科）

一、非手术/药物治疗方案

适用人群：初诊标准风险患者、老年或合并症不宜强化疗者、维持治疗阶段。

• •诱导化疗（如“7+3”方案）：阿糖胞苷+柔红霉素，含骨髓穿刺、血常规、肝肾功、心电图等检查费：¥12,000–¥28,000/周期（3–4周）
• •去甲基化治疗（地西他滨/阿扎胞苷）：适用于≥60岁或 unfit 患者，含每月骨穿及MRD监测：¥18,000–¥35,000/疗程（6个月）
• •靶向治疗（FLT3抑制剂吉瑞替尼、IDH抑制剂艾伏尼布）：需基因检测（¥3,200–¥5,800），年药费：¥240,000–¥420,000（医保谈判后自付约¥30,000–¥90,000/年）

二、根治性治疗方案

适用人群：中高危初治患者、首次完全缓解后巩固治疗者。

• •异基因造血干细胞移植（allo-HSCT）：含HLA配型（¥2,500）、预处理化疗、供者动员采集、回输及GVHD防治，全程住院约100天：¥350,000–¥680,000（不含供者费用）

三、特殊复杂情况

• •复发/难治性AML：Venetoclax联合阿扎胞苷（年药费¥320,000，医保后自付约¥75,000）；CAR-T临床试验（部分免费，常规治疗费另计）
• •伴严重感染/出血并发症：ICU支持、广谱抗真菌/抗细菌治疗、成分输血，单次加重期费用：¥45,000–¥120,000

四、方案快速选择指南

• •预算有限/老年患者：首选去甲基化±靶向药（年总支出¥60,000–¥150,000）
• •中青年标准风险患者：强化疗→移植（首年总投入¥400,000–¥750,000）
• •复发耐药者：优先入组规范临床试验或Venetoclax联合方案